



## Clinical trial results:

### Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity upon House Dust Mite Skin Challenge in Patients Suffering from Moderate to Severe Atopic Dermatitis

#### Summary

EudraCT number	2016-002539-14
Trial protocol	GB
Global end of trial date	04 December 2017

#### Results information

Result version number	v1 (current)
This version publication date	13 October 2021
First version publication date	13 October 2021

#### Trial information

##### Trial identification

Sponsor protocol code	ANB020-002
-----------------------	------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	AnaptysBio Inc.
Sponsor organisation address	10421 Pacific Center Court, Suite 200, San Diego, CA, United States, 92121
Public contact	AnaptysBio Clinical Trials Info, AnaptysBio Inc, +1 8583626387, clinicaltrialinfo@anaptysbio.com
Scientific contact	AnaptysBio Clinical Trials Info, AnaptysBio Inc, +1 8583626387, clinicaltrialinfo@anaptysbio.com

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	04 December 2017
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	04 December 2017
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

- To measure the decrease of cytokines within interstitial fluid, where saline and house dust mite (HDM) have been administered, in patients receiving ANB020 compared to placebo.
- To assess the effect of ANB020 on differential white blood cell (WBC) counts.
- To assess the safety and tolerability of single dose administration of ANB020 in patients with atopic dermatitis (AD).

Protection of trial subjects:

The study was conducted in accordance with the protocol, the ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, applicable International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines, and applicable laws and regulations.

The study protocol, all study protocol amendments, written study patient information, informed consent form (ICF), Investigator's Brochure and any other relevant documents were reviewed and approved by an independent ethics committee (IEC) at the study center.

An informed consent document approved by the study center's IEC was signed by the patient or their legally authorized representative and the authorized person obtaining the informed consent before the participant was entered in the study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	06 March 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 14
Worldwide total number of subjects	14
EEA total number of subjects	0

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23	0

months)	
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	14
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 14 (100%) patients were screened in the study. Of these, 12 (85.7%) patients received placebo and ANB020. Two (14.3%) patients discontinued the study prior to ANB020 or placebo administration with the reported reason as patient withdrew consent.

### Pre-assignment period milestones

Number of subjects started	14
----------------------------	----

Number of subjects completed	12
------------------------------	----

### Pre-assignment subject non-completion reasons

Reason: Number of subjects	Consent withdrawn by subject: 2
----------------------------	---------------------------------

### Period 1

Period 1 title	Overall Study (overall period)
----------------	--------------------------------

Is this the baseline period?	Yes
------------------------------	-----

Allocation method	Not applicable
-------------------	----------------

Blinding used	Not blinded
---------------	-------------

### Arms

Arm title	ANB020
-----------	--------

Arm description:

Participants received an intravenous (IV) dose of placebo saline on Day 1. On Day 4, participants returned to the study center for a skin challenge test with saline control and house dust mite (HDM) allergen. Approximately 1 hour after the HDM skin challenge, suction blister cups were applied to the site of injection to generate a blister.

On Day 8, participants with a positive response to the HDM skin challenge test received 300 mg ANB020 IV. On Day 11 participants returned to the study center for the skin challenge with saline and HDM. Approximately 1 hour after the HDM skin challenge, suction blister cups were applied to the site of injection to generate a blister.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Placebo
--	---------

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Solution for infusion
----------------------	-----------------------

Routes of administration	Intravenous use
--------------------------	-----------------

Dosage and administration details:

Sterile normal saline (0.9% NaCl) for injection.

Investigational medicinal product name	ANB020
--	--------

Investigational medicinal product code	ANB020
--	--------

Other name	
------------	--

Pharmaceutical forms	Solution for infusion
----------------------	-----------------------

Routes of administration	Intravenous use
--------------------------	-----------------

Dosage and administration details:

ANB020 was administered as a single IV dose of 300 mg/100 mL.

Number of subjects in period 1 <sup>[1]</sup>	ANB020
Started	12
Completed	12

---

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Two patients discontinued the study prior to ANB020 or placebo administration.

## Baseline characteristics

### Reporting groups

Reporting group title	ANB020
-----------------------	--------

Reporting group description:

Participants received an intravenous (IV) dose of placebo saline on Day 1. On Day 4, participants returned to the study center for a skin challenge test with saline control and house dust mite (HDM) allergen. Approximately 1 hour after the HDM skin challenge, suction blister cups were applied to the site of injection to generate a blister.

On Day 8, participants with a positive response to the HDM skin challenge test received 300 mg ANB020 IV. On Day 11 participants returned to the study center for the skin challenge with saline and HDM. Approximately 1 hour after the HDM skin challenge, suction blister cups were applied to the site of injection to generate a blister.

Reporting group values	ANB020	Total	
Number of subjects	12	12	
Age categorical			
Units: Subjects			
18 - 65 years	12	12	
Age continuous			
Units: years			
arithmetic mean	40.4		
standard deviation	± 13.45	-	
Gender categorical			
Units: Subjects			
Female	1	1	
Male	11	11	
Race			
Units: Subjects			
White	12	12	

## End points

### End points reporting groups

Reporting group title	ANB020
-----------------------	--------

Reporting group description:

Participants received an intravenous (IV) dose of placebo saline on Day 1. On Day 4, participants returned to the study center for a skin challenge test with saline control and house dust mite (HDM) allergen. Approximately 1 hour after the HDM skin challenge, suction blister cups were applied to the site of injection to generate a blister.

On Day 8, participants with a positive response to the HDM skin challenge test received 300 mg ANB020 IV. On Day 11 participants returned to the study center for the skin challenge with saline and HDM. Approximately 1 hour after the HDM skin challenge, suction blister cups were applied to the site of injection to generate a blister.

Subject analysis set title	Placebo
----------------------------	---------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

Participants received a placebo IV infusion on Day 1.

Subject analysis set title	ANB020
----------------------------	--------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

Participants received 300 mg ANB020 by IV infusion on Day 8.

### Primary: Interleukin-4 (IL-4) Concentration in Blister Fluid

End point title	Interleukin-4 (IL-4) Concentration in Blister Fluid <sup>[1]</sup>
-----------------	--

End point description:

Within 24 hours of the saline and HDM skin challenge (Days 5 and 12), blister fluid was aspirated with a 30-gauge needle. Cytokine concentrations were measured using validated assay methods. The lower limit of quantitation (LLOQ) for IL-4 is 6.46 pg/mL.

End point type	Primary
----------------	---------

End point timeframe:

Day 5 (4 days after placebo infusion) and Day 12 (4 days after infusion with ANB020)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Inferential statistical analysis of cytokine concentrations in blister fluid was not performed due to < 5 paired data points.

End point values	Placebo	ANB020		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	0 <sup>[2]</sup>	0 <sup>[3]</sup>		
Units: pg/mL				
arithmetic mean (standard deviation)				
Saline control	()	()		
House dust mite extract	()	()		

Notes:

[2] - All participants had concentrations below lower limit of quantification

[3] - All participants had concentrations below lower limit of quantification

### Statistical analyses

No statistical analyses for this end point

### Primary: Interleukin-5 (IL-5) Concentration in Blister Fluid

End point title	Interleukin-5 (IL-5) Concentration in Blister Fluid <sup>[4]</sup>
End point description:	
Within 24 hours of the saline and HDM skin challenge (Days 5 and 12), blister fluid was aspirated with a 30-gauge needle. Cytokine concentrations were measured using validated assay methods. The LLOQ for IL-5 is 1.16 pg/mL. "99999" indicates values that were below the LLOQ or could not be calculated.	
End point type	Primary
End point timeframe:	
Day 5 and Day 12	

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Inferential statistical analysis of cytokine concentrations in blister fluid was not performed due to < 5 paired data points.

End point values	Placebo	ANB020		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	12 <sup>[5]</sup>	12 <sup>[6]</sup>		
Units: pg/mL				
arithmetic mean (standard deviation)				
Saline control	1.88 (± 2.462)	99999 (± 99999)		
House dust mite extract	1.73 (± 1.648)	2.47 (± 2.583)		

Notes:

[5] - 4 and 5 subjects had concentrations ≥ LLOQ after saline and HDM challenge, respectively.

[6] - 1 and 5 subjects had concentrations ≥ LLOQ after saline and HDM challenge, respectively.

## Statistical analyses

No statistical analyses for this end point

## Primary: Interleukin-13 (IL-13) Concentration in Blister Fluid

End point title	Interleukin-13 (IL-13) Concentration in Blister Fluid <sup>[7]</sup>
End point description:	
Within 24 hours of the saline and HDM skin challenge (Days 5 and 12), blister fluid was aspirated with a 30-gauge needle. Cytokine concentrations were measured using validated assay methods. The LLOQ for IL-13 is 90.96 pg/mL.	
End point type	Primary
End point timeframe:	
Day 5 and Day 12	

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Inferential statistical analysis of cytokine concentrations in blister fluid was not performed due to < 5 paired data points.

End point values	Placebo	ANB020		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	12 <sup>[8]</sup>	12 <sup>[9]</sup>		
Units: pg/mL				
arithmetic mean (standard deviation)				
Saline control	131.90 (± 122.626)	160.84 (± 136.219)		
House dust mite extract	137.13 (± 110.450)	135.99 (± 168.476)		



Notes:

[8] - 5 and 6 subjects had concentrations  $\geq$  LLOQ after saline and HDM challenge, respectively.

[9] - 6 and 4 subjects had concentrations  $\geq$  LLOQ after saline and HDM challenge, respectively.

## Statistical analyses

No statistical analyses for this end point

### Primary: Interleukin-33 (IL-33) Concentration in Blister Fluid

End point title	Interleukin-33 (IL-33) Concentration in Blister Fluid <sup>[10]</sup>
-----------------	---

End point description:

Within 24 hours of the saline and HDM skin challenge (Days 5 and 12), blister fluid was aspirated with a 30-gauge needle. Cytokine concentrations were measured using validated assay methods. The LLOQ for IL-33 is 4.44 pg/mL.

End point type	Primary
----------------	---------

End point timeframe:

Day 5 and Day 12

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Inferential statistical analysis of cytokine concentrations in blister fluid was not performed due to < 5 paired data points.

End point values	Placebo	ANB020		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	0 <sup>[11]</sup>	0 <sup>[12]</sup>		
Units: pg/mL				
arithmetic mean (standard deviation)				
Saline control	()	()		
House dust mite extract	()	()		

Notes:

[11] - All participants had concentrations < LLOQ

[12] - All participants had concentrations < LLOQ

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants with Treatment-emergent Adverse Events

End point title	Number of Participants with Treatment-emergent Adverse Events <sup>[13]</sup>
-----------------	---

End point description:

Treatment emergent adverse events (TEAEs) are AEs that started or worsened in severity on or after the date and time of the study drug infusion or if the event represents an exacerbation of a condition observed pre-treatment.

A serious AE is any untoward medical occurrence that at any dose:

- Resulted in death;
- Was life-threatening;
- Required inpatient hospitalization or prolongation of existing hospitalization;
- Resulted in persistent or significant disability/incapacity;
- Was a congenital abnormality/birth defect.
- Other: Medically significant events, which did not meet any of the criteria above, but may have jeopardized the patient and may have required medical or surgical intervention to prevent one of the other serious outcomes listed above.

A severe AE is defined as an event that interrupted the patient's usual daily activity.

End point type	Primary
----------------	---------

End point timeframe:

For Placebo, Day 1 to Day 8; For ANB020 from Day 8 to Day 148.

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Inferential statistical analysis of safety data were not planned.

End point values	Placebo	ANB020		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	12	12		
Units: participants				
Any treatment-emergent adverse event (TEAE)	8	11		
Any treatment-emergent serious AE (TESAE)	0	1		
TEAE leading to study drug discontinuation	0	0		
TEAE leading to study drug interruption	0	0		
TEAE leading to study drug dose reduction	0	0		
TEAE leading to discontinuation of study	0	0		
Related TEAEs	0	10		
Severe TEAEs	0	0		
Deaths due to TEAE	0	0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Longest Wheal Diameter

End point title	Longest Wheal Diameter
-----------------	------------------------

End point description:

Urticarial response (longest wheal diameter) was measured 30 minutes after the HDM skin challenge test.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 4 (placebo) and Day 11 (ANB020), 30 minutes after the saline and HDM challenge.

End point values	Placebo	ANB020		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	12	12		
Units: mm				
arithmetic mean (standard deviation)				
Saline control	0.1 (± 0.29)	0.0 (± 0.00)		
House dust mite extract	8.3 (± 2.96)	7.9 (± 3.23)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maximum Observed Concentration (C<sub>max</sub>) of ANB020

End point title	Maximum Observed Concentration (C <sub>max</sub> ) of ANB020
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Day 8 at predose, 0.5 hours after the start of infusion, end of infusion, and 3 hours and 6 hours after the end of infusion.

End point values	ANB020			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: µg/mL				
geometric mean (geometric coefficient of variation)	115.6 (± 39.9)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Time to Maximum Observed Concentration (T<sub>max</sub>) of ANB020

End point title	Time to Maximum Observed Concentration (T <sub>max</sub> ) of ANB020
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Day 8 at predose, 0.5 hours after the start of infusion, end of infusion, and 3 hours and 6 hours after the end of infusion.

<b>End point values</b>	ANB020			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: hours				
median (full range (min-max))	1.180 (1.00 to 7.03)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Area Under the Concentration-time Curve in Serum from Time Zero (Predose) Extrapolated to Infinite Time (AUC0-inf) of ANB020

End point title	Area Under the Concentration-time Curve in Serum from Time Zero (Predose) Extrapolated to Infinite Time (AUC0-inf) of ANB020
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Day 8 at predose, 0.5 hours after the start of infusion, end of infusion, and 3 hours and 6 hours after the end of infusion.

<b>End point values</b>	ANB020			
Subject group type	Reporting group			
Number of subjects analysed	9 <sup>[14]</sup>			
Units: h × µg/mL				
geometric mean (geometric coefficient of variation)	21110 (± 32.4)			

Notes:

[14] - Three subjects excluded due to percentage of AUC(0-inf) obtained by extrapolation > 20.0%

### Statistical analyses

No statistical analyses for this end point

### Secondary: Area Under the Serum Concentration-time Curve from Time Zero to the Time of the Last Quantifiable Concentration (AUClast) for ANB020

End point title	Area Under the Serum Concentration-time Curve from Time Zero to the Time of the Last Quantifiable Concentration (AUClast) for ANB020
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Day 8 at predose, 0.5 hours after the start of infusion, end of infusion, and 3 hours and 6 hours after the end of infusion.

<b>End point values</b>	ANB020			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: h × µg/mL				
geometric mean (geometric coefficient of variation)	13740 (± 90.5)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Apparent Terminal Half-life (t<sub>1/2</sub>) of ANB020

End point title	Apparent Terminal Half-life (t <sub>1/2</sub> ) of ANB020
End point description:	
End point type	Secondary
End point timeframe:	
Day 8 at predose, 0.5 hours after the start of infusion, end of infusion, and 3 hours and 6 hours after the end of infusion.	

<b>End point values</b>	ANB020			
Subject group type	Reporting group			
Number of subjects analysed	10 <sup>[15]</sup>			
Units: hours				
geometric mean (geometric coefficient of variation)	241.7 (± 52.8)			

Notes:

[15] - Two subjects excluded due to a goodness-of-fit statistic for calculation of λ<sub>Z</sub> (Rsq) < 0.800

### Statistical analyses

No statistical analyses for this end point

### Secondary: Systemic Clearance (CL) of ANB020

End point title	Systemic Clearance (CL) of ANB020
End point description:	
End point type	Secondary
End point timeframe:	
Day 8 at predose, 0.5 hours after the start of infusion, end of infusion, and 3 hours and 6 hours after the end of infusion.	

<b>End point values</b>	ANB020			
Subject group type	Reporting group			
Number of subjects analysed	9 <sup>[16]</sup>			
Units: L/h				
geometric mean (geometric coefficient of variation)	0.01422 ( $\pm$ 32.3)			

Notes:

[16] - Three subjects excluded due to percentage of AUC(0-inf) obtained by extrapolation > 20.0%

## Statistical analyses

No statistical analyses for this end point

### Secondary: Volume of Distribution at Steady State Following IV Dosing of ANB020 (Vss)

End point title	Volume of Distribution at Steady State Following IV Dosing of ANB020 (Vss)
End point description:	
End point type	Secondary
End point timeframe:	
Day 8 at predose, 0.5 hours after the start of infusion, end of infusion, and 3 hours and 6 hours after the end of infusion.	

<b>End point values</b>	ANB020			
Subject group type	Reporting group			
Number of subjects analysed	9 <sup>[17]</sup>			
Units: liters				
geometric mean (geometric coefficient of variation)	5.354 ( $\pm$ 37.2)			

Notes:

[17] - Three subjects excluded due to percentage of AUC(0-inf) obtained by extrapolation > 20.0%

## Statistical analyses

No statistical analyses for this end point

### Secondary: Serum IL-4 Concentration

End point title	Serum IL-4 Concentration
End point description:	
Cytokine concentrations were measured using validated assay methods. The lower limit of quantitation (LLOQ) for IL-4 is 6.46 pg/mL.	
End point type	Secondary
End point timeframe:	
Baseline (Day 1 for Placebo and Day 8 for ANB020) and 5 days after study drug administration (Day 5	

End point values	Placebo	ANB020		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	0 <sup>[18]</sup>	0 <sup>[19]</sup>		
Units: pg/mL				
arithmetic mean (standard deviation)				
Baseline	()	()		
5 days after study drug administration	()	()		

Notes:

[18] - All participants had concentrations below lower limit of quantification

[19] - All participants had concentrations below lower limit of quantification

### Statistical analyses

No statistical analyses for this end point

### Secondary: Serum IL-5 Concentration

End point title	Serum IL-5 Concentration
End point description:	
Cytokine concentrations were measured using validated assay methods. The LLOQ for IL-5 is 1.16 pg/mL.	
End point type	Secondary
End point timeframe:	
Baseline and 5 days after study drug administration	

End point values	Placebo	ANB020		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	0 <sup>[20]</sup>	0 <sup>[21]</sup>		
Units: pg/mL				
arithmetic mean (standard deviation)				
Baseline	()	()		
5 days after study drug administration	()	()		

Notes:

[20] - All participants had concentrations less than the LLOQ

[21] - All participants had concentrations less than the LLOQ

### Statistical analyses

No statistical analyses for this end point

### Secondary: Serum IL-13 Concentration

End point title	Serum IL-13 Concentration
End point description:	
Cytokine concentrations were measured using validated assay methods. The LLOQ for IL-13 is 90.96 pg/mL.	

End point type	Secondary
End point timeframe:	
Baseline and 5 days after study drug administration	

End point values	Placebo	ANB020		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	0 <sup>[22]</sup>	0 <sup>[23]</sup>		
Units: pg/mL				
arithmetic mean (standard deviation)				
Baseline	()	()		
5 days after study drug administration	()	()		

Notes:

[22] - All participants had concentrations < LLOQ

[23] - All participants had concentrations < LLOQ

### Statistical analyses

No statistical analyses for this end point

### Secondary: Serum IL-33 Concentration

End point title	Serum IL-33 Concentration
End point description:	
Cytokine concentrations were measured using validated assay methods. The LLOQ for IL-33 is 4.44 pg/mL.	
End point type	Secondary
End point timeframe:	
Baseline and 5 days after study drug administration	

End point values	Placebo	ANB020		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	0 <sup>[24]</sup>	0 <sup>[25]</sup>		
Units: pg/mL				
arithmetic mean (standard deviation)				
Baseline	()	()		
5 days after study drug administration	()	()		

Notes:

[24] - All participants had concentrations < LLOQ

[25] - All participants had concentrations < LLOQ

### Statistical analyses

No statistical analyses for this end point

### Secondary: Serum Soluble Specific Cell-surface Receptor (sST2) Concentration

End point title	Serum Soluble Specific Cell-surface Receptor (sST2) Concentration
-----------------	---



End point description:

The concentration of sST2 in serum was measured using a quantitative sandwich monoclonal enzyme-linked immunosorbant assay (ELISA). The LLOQ for sST2 was determined to be 3.13 ng/mL.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and 5 days after study drug administration

End point values	Placebo	ANB020		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	12	12		
Units: µg/L				
arithmetic mean (standard deviation)				
Baseline	34.04 (± 8.531)	33.99 (± 9.089)		
5 days after study drug administration	34.90 (± 8.800)	35.67 (± 10.417)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Ex-Vivo Induced Interferon-gamma (IFN-γ) Levels

End point title	Ex-Vivo Induced Interferon-gamma (IFN-γ) Levels
-----------------	---

End point description:

Whole blood samples were stimulated with interleukin-12 and interleukin-33 to determine the affect of ANB020 on inhibition of cytokine-induced interferon gamma. IFN-γ concentrations were measured using validated assay methods. The LLOQ of IFN-γ was 146.56 ng/L. "99999" indicates values below the LLOQ.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 1, 11, 64, 120 and 148

End point values	ANB020			
Subject group type	Reporting group			
Number of subjects analysed	12 <sup>[26]</sup>			
Units: ng/L				
arithmetic mean (standard deviation)				
Day 1 (Baseline)	4379.77 (± 4221.941)			
Day 11	99999 (± 99999)			
Day 64	629.65 (± 923.419)			
Day 120	3210.27 (± 2963.587)			

Day 148	3107.01 ( $\pm$ 2420.356)			
---------	---------------------------	--	--	--

Notes:

[26] - The number of subjects with levels  $\geq$  LLOQ was 12, 0, 8, 11, and 11 at each time point respectively

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants with Anti-drug Antibodies

End point title	Number of Participants with Anti-drug Antibodies
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Samples for ADA detection were collected on Days 1, 11, 64, 120, and 148

End point values	ANB020			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: participants				
Day 1 (Baseline)	1			
Day 11	0			
Day 64	2			
Day 120	3			
Day 148	3			

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Placebo: Day 1 to Day 8

ANB020: Day 8 to Day 148

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.1
--------------------	------

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Participants received a placebo IV infusion on Day 1.

Reporting group title	ANB020
-----------------------	--------

Reporting group description:

Participants received 300 mg ANB020 by IV infusion on Day 8.

Serious adverse events	Placebo	ANB020	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Placebo	ANB020	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 12 (66.67%)	11 / 12 (91.67%)	
Investigations			
Haemoglobin decreased			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	
occurrences (all)	0	1	
Monocyte count decreased			

subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	
Neutrophil count decreased subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	
Injury, poisoning and procedural complications Accident subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	
Arthropod bite subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	
Clavicle fracture subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	
Contusion subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0	
Vascular disorders Hot flush subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	
Hypertension subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0	
Peripheral coldness subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0	
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	3 / 12 (25.00%) 3	4 / 12 (33.33%) 5	
Headache subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	3 / 12 (25.00%) 3	
Migraine			

subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	
Paraesthesia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	
Presyncope subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0	
General disorders and administration site conditions			
Peripheral swelling subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	2 / 12 (16.67%) 2	
Chest pain subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	
Fatigue subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	
Infusion site pain subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0	
Ear and labyrinth disorders			
Tinnitus subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	
Gastrointestinal disorders			
Dyspepsia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	
Nausea subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 3	
Vomiting subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	
Respiratory, thoracic and mediastinal disorders			

Cough subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	1 / 12 (8.33%) 1	
Nasal congestion subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	
Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0	
Skin and subcutaneous tissue disorders Urticaria subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	2 / 12 (16.67%) 2	
Psychiatric disorders Stress subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	
Bursitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	
Pain in extremity subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	
Infections and infestations Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	2 / 12 (16.67%) 2	
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	2 / 12 (16.67%) 2	
Skin infection			

subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	
occurrences (all)	0	1	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
08 November 2016	<p>Amendment 1 implemented the following changes:</p> <ul style="list-style-type: none"><li>• Secondary objectives updated to include:<ul style="list-style-type: none"><li>o Assess ex vivo PD activity of ANB020 on IFN-<math>\gamma</math> levels.</li><li>o Test for immunogenicity to ANB020.</li></ul></li><li>• Summary of study design updated regarding additional PK draws, PD/ADA, and clinical assessments.</li><li>• Schematic of study design updated to reflect the changes in protocol design.</li><li>• Schedule of Events was updated to reflect changes in study conduct which includes:<ul style="list-style-type: none"><li>o Update of additional study center visits at Day 85, 120, and 148.</li><li>o Additional telephone contact visit at Day 99.</li><li>o Additional PK draws on Day 120 and Day 148.</li><li>o Whole blood sampling for ex vivo IFN-<math>\gamma</math> (Day 1, 11, 64, 120 and 148).</li><li>o Serum sampling for ADA (Day 1, 11, 64, 120, and 148).</li><li>o EASI, IGA, SCORAD, DLQI, 5Ditch, corticosteroid use obtained on Day 85, 120, 148.</li><li>o Urinalysis and safety laboratory assessments to Day 85, 120, and 148.</li><li>o Moved physical examination and pregnancy test to Day 148 from Day 64.</li><li>o Diary checked at Day 85, 99, 120, and 148.</li><li>o Concomitant medications/AEs at each new time point.</li></ul></li><li>• Inclusion criteria and Patient restrictions modified to describe methods and duration of contraception for women of childbearing potential and male patients to ensure all patients are using highly effective methods of contraception throughout the study.</li><li>• Section 4.3.5 modified to account for EOS to be Day 148 for AEs/SAE follow-up to reflect the changes in study conduct.</li><li>• Blinding modified to accurately reflect the study is not blinded and changes in the study conduct.</li><li>• Excluded medications modified to include: Any live attenuated vaccine within 4 weeks of screening and for the duration of the study (Day 148) or for 140 days post last dose of study drug.</li><li>• Table of blood volume updated.</li><li>• Pharmacodynamics, safety analyses, vital signs measurements, physical findings and clinical laboratory evaluation were updated to reflect the changes in study conduct.</li></ul>
01 December 2016	<p>Amendment 2 implemented the following changes:</p> <ul style="list-style-type: none"><li>• HIV criteria were added in the Exclusion criteria and the list of abbreviations was updated.</li><li>• Exclusion Criteria was updated with text regarding enrollment of patients with positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV 1 and 2 antibodies at screening to ensure the safety of potential patients that were to be enrolled.</li></ul>

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported